BRAF and metastatic colorectal cancer: Median (Med) overall survival and progression free survival (months) after different treatment regimens in a population‐based Scandinavian cohort of metastatic colorectal cancer patients (n = 583) according to MSI status (left side) and MSI and BRAF‐mutation status combined (right side)